Summer Sale
50% off Premium Yearly
Opinions Robert McWhirter
Acasti PharmaACST.VCOMMENTJan 02, 2015
Robert McWhirterStock price when the opinion was issued
As of Feb 16, 2023. Market Open.
You might be interested:
The krill oil lipid trial did not work as expected. The overall portfolio is quite attractive. Over the coming year, there may be opportunities. However, there are other opportunities in other companies like ATE, which he owns.
Robert McWhirterRobert McWhirterRobert McWhirter
Robert McWhirterPretty disappointing after last fall's announcement to have an Asian pharma company come in and get the rights to CaPre, their phase-3 development drug to treat cholesterol. It looked promising, but ACST hold off on the deal after a few new parties showed interest in CaPre. The market is disappointed the deal didn't happen and punished this stock. He believes this company could be worth $1 billion in two three years. The promise is still there, but you have to wait. Watch the phase 3 drug trials into next year.
Alex RuusA company with no revenue now. Drug developer. They are into phase 3 trials. A $33 million market cap company with half that in cash in their balance sheet. Probably going to be taken out by a large pharma once the drug is approved. (Analysts’ price target is $5.21)
Alex RuusGot beaten up recently, because they just did a financing. (He has 3% of the financing.) A compelling opportunity and a great entry point. They are going to be initiating phase 3 trials this month. Just raised some money and have enough to do the trial now. In negotiations with a big Chinese Pharma in terms of licensing Asian rights. Has been presented with an opportunity for about $125 million deal with the Chinese, which they are still negotiating. They have the cash on the balance sheet, so there are no near-term financial pressures.
Alex RuusA spin-out out of Neptune (NEPT-T), which still owns 35% of the company. There are positive developments going on and they are getting very close to going forward with phase 3. Discussions have been going on with the FDA. It’s fallen off the radar screen and there isn’t much in terms of analysts’ coverage. Expects there will be news this fall and winter which should really catalyze the stock. A good time to accumulate the stock.
Acasti Pharma (APO-X) and Neptune Tech & Bioresource (NTB-T) comparison? The key for both companies is the use of krill to extract fish oil. The target would be for high lipids in blood. They can be taken alone or used in combination with statin drugs. The testing has been finished and it works. This stock is covered by only one analyst who is forecasting they are going to lose $0.06 in February year end, but will turn around and earn $0.22 in 2016. Speculative.